Association between the NQO1 C609T Polymorphism with Hepatocellular Carcinoma Risk in the Chinese Population

  • Zhao, Hong (Department of Radiology, Institute: the Second Hospital of Anhui Medical University) ;
  • Zou, Li-Wei (Department of Radiology, Institute: the Second Hospital of Anhui Medical University) ;
  • Zheng, Sui-Sheng (Department of Radiology, Institute: the Second Hospital of Anhui Medical University) ;
  • Geng, Xiao-Ping (Department of Radiology, Institute: the Second Hospital of Anhui Medical University)
  • Published : 2015.03.18


Background: Associations between the NQO1 C609T polymorphism and hepatocellular carcinoma (HCC) risk are a subject of debate. We therefore performed the present meta-analysis to evaluate links with HCC susceptibility. Materials and Methods: Several major databases (PubMed, EBSCO), the Chinese national knowledge infrastructure (CNKI) and the Wanfang database were searched for eligible studies. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to measure the strength of associations. Results: A total of 4 studies including 1,325 patients and 1,367 controls were identified. There was a significant association between NQO1 C609T polymorphism and HCC for all genetic models (allelic model: OR=1.45, 95%CI=1.23-1.72, p<0.01; additive model: OR=1.96, 95%CI=1.57-2.43, p<0.01; dominant model: OR=1.62, 95%CI=1.38-1.91, p<0.01; and recessive model: OR=1.53, 95%CI=1.26-1.84, p<0.01). On subgroup analysis, similarly results were identified in Asians. For Asians, the combined ORs and 95% CIs were (allelic model: OR=1.50, 95%CI=1.24-1.82, p<0.01; additive model: OR=2.11, 95%CI=1.48-3.01, p<0.01; dominant model: OR=1.69, 95%CI=1.42-2.02, p<0.01; and recessive model: OR=1.59, 95%CI=1.16-2.19, p<0.01). Conclusions: The current meta-analysis suggested that the NQO1 C609T polymorphism could be a risk factor for developing HCC, particularly in the Chinese population.


Hepatocellular carcinoma;NQO1;polymorphism;meta-analysis;Chinese


  1. Akkiz H, Bayram S, Bekar A, et al (2010). No association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and risk of hepatocellular carcinoma development in Turkish subjects. Asian Pac J Cancer Prev, 11, 1051-8.
  2. Bowen DG, Walker CM (2005). Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature, 436, 946-52.
  3. de Lope CR, Tremosini S, Forner A, et al (2012). Management of HCC. J Hepatol, 56, 75-87.
  4. Dinkova-Kostova AT, Talalay P (2010). NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys, 501, 116-23.
  5. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
  6. El-Serag HB, Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-76.
  7. Farazi PA, DePinho RA (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer, 6, 674-87.
  8. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
  9. Hu X, Zhang Z, Ma D, et al (2010). TP53, MDM2, NQO1, and susceptibility to cervical cancer. Cancer Epidemiol Biomarkers Prev, 19, 755-61.
  10. Kato N, Ji G, Wang Y, et al (2005). Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology, 42, 846-53.
  11. Kim YJ, Lee HS (2005). Single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Intervirology, 48, 10-5.
  12. Lau J, Ioannidis JP, Schmid CH (1997). Quantitative synthesis in systematic reviews. Ann Intern Med, 127, 820-6.
  13. Liu F, Luo L, Wei Y, et al (2013). A functional NQO1 609C>T polymorphism and risk of hepatocellular carcinoma in a Chinese population. Tumour Biol, 34, 47-53.
  14. Malik MA, Zargar SA, Mittal B (2011). Role of NQO1 609C>T and NQO2-3423G>A polymorphisms in susceptibility to gastric cancer in Kashmir valley. DNA Cell Biol, 30, 297-303.
  15. Mandal RK, Nissar K, Mittal RD (2012). Genetic variants in metabolizing genes NQO1, NQO2, MTHFR and risk of prostate cancer: a study from North India. Mol Biol Rep, 39, 11145-52.
  16. Moher D, Liberati A, Tetzlaff J, et al (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med, 151, 264-9.
  17. Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43.
  18. Peng XE, Jiang YY, Shi XS, et al (2013). NQO1 609C>T polymorphism interaction with tobacco smoking and alcohol drinking increases colorectal cancer risk in a Chinese population. Gene, 521, 105-10.
  19. Siegel D, Yan C, Ross D (2012). NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol, 83, 1033-40.
  20. Tan SK, Qiu XQ, Tang GF, et al (2012). Relationship between hepatocellular carcinoma and the interaction between NQO1 polymorphisms and environmental factors. Zhonghua Gan Zang Bing Za Zhi, 20, 833-7.
  21. Traver RD, Siegel D, Beall HD, et al (1997). Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer, 75, 69-75.
  22. Wang WW, Chen GY, Sun JJ, et al (2013). The relationship between polymorphisms of NQO1 genes and hepatocellular carcinoma in Zhengzhou and Guilin areas. Chin J Hepatobiliary Surg, 19, 836-40.
  23. Yuan W, Xu L, Chen W, et al (2011). Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat, 125, 467-72.
  24. Yuen MF, Hou JL, Chutaputti A, et al (2009). Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol, 24, 346-53.